Research Grade Lintuzumab (DHD37502)

Description

Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).

Catalog No.

DHD37502

Host species

Humanized

Species reactivity

Human

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Concentration

1 mg/ml

Purity

>95% by SDS-PAGE.

Clonality

Monoclonal

Isotype

IgG1-kappa

Applications

Research Grade Biosimilar

Target

Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3

Purification

Protein A or G purified from cell culture supernatant.

Endotoxin level

Please contact with the lab for this information.

Expression system

XtenCHO

Accession

P20138

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Alternative Names

225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3

Note

For research use only. Not suitable for clinical or therapeutic use.